WOBURN, Mass. , Dec. 02, 2021 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors